Group 1 - The stock of Sanofi Pharmaceuticals-B (02257) increased by over 17% during trading, with a current rise of 15.84% to HKD 11.85, and a trading volume of HKD 15.0443 million [1] - Sanofi Pharmaceuticals-B reported a significant decline in other income, which amounted to USD 12.4 thousand, a year-on-year decrease of 87.4%. The company recorded a loss attributable to shareholders of USD 3.698 million, which represents a year-on-year narrowing of 91% [1] - The reduction in losses is attributed to several factors, including a decrease in fair value losses on financial assets, reduced R&D expenses, lower administrative expenses, and a decrease in fair value losses on financial liabilities [1] Group 2 - Sanofi Pharmaceuticals-B's core products include STP705, STP707, and STP122G, with STP705 being the most advanced in development and expected to be the company's first commercial product by 2025 [2] - STP705 is a dual-target siRNA that simultaneously targets TGF-β1 and COX-2, and it is the first and only drug in the siRNA cancer treatment field to achieve positive Phase II clinical results. In the Phase II trial for basal cell carcinoma, the 180ug dosage group achieved a 100% complete clearance rate [2] - The company is expanding the indications for STP705, having initiated Phase II clinical trials for scars, Phase I clinical trials for adult abdominal liposuction, and Phase I clinical trials for liver cancer. Additionally, STP705 has received orphan drug designation for the treatment of cholangiocarcinoma and primary sclerosing cholangitis [2]